A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of BI 1810631 in the Blood
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06028464
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT06013969
- Locations
- 🇲🇾
Hospital Pulau Pinang-Pulau Pinang-21953, Georgetown Pulau Pinang, Malaysia
🇪🇸Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸AXIS Clinicals, Fargo, North Dakota, United States
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT06006585
- Locations
- 🇺🇸
Retina Consultants of Houston, PA-Houston-62050, Houston, Texas, United States
🇺🇸Retina Consultants of Texas-The Woodlands-67575, The Woodlands, Texas, United States
🇺🇸Bay Area Retina Associates - Walnut Creek, Walnut Creek, California, United States
A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT06006598
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT05990738
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
🇫🇷INS Curie, Paris, France
A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT05985200
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT05970640
- Locations
- 🇺🇸
Velocity Clinical Research-Chula Vista-67286, Chula Vista, California, United States
🇺🇸Velocity Clinical Research-La Mesa-69117, La Mesa, California, United States
🇺🇸Catalina Research Institute, LLC-Montclair-49051, Montclair, California, United States
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
- Conditions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 330
- Registration Number
- NCT05966740
- Locations
- 🇺🇸
MUSC (Medical university of South Carolina), Charleston, South Carolina, United States
🇺🇸University of California, San Diego, La Jolla, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
Describing Patient With DME, Their Patient Journey and Disease Progression
- Conditions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 221004
- Registration Number
- NCT05966753
- Locations
- 🇺🇸
CorEvitas HQ, Waltham, Massachusetts, United States
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the Blood
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT05965583
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany